IJNII - International Journal of Nursing Innovations and Insights
Volume 3, Issue 2 | October-2025
e-ISSN: 2998-3142 Print ISSN: 2998-3118

Optimizing Hemodynamic Stability: Nursing Strategies and Pharmacologic Management in Cardiovascular Disorders

Dr. Maryam Al-Sabah[1], Dr. Abdullah Al-Mutairi[2]
[1]College of Nursing, Kuwait University, Kuwait City, Kuwait
[2]Department of Health Sciences, Gulf University for Science and Technology, Hawally, Kuwait
Received: 13-08-2025; Revised: 12-09-2025; Accepted: 25-09-2025; Published: 09-10-2025

Abstract

The issue of cardiovascular diseases (CVDs) is still a leading cause of morbidity and mortality in the global population, so it requires high-tech and evidence-based clinical treatment. The vasoactive drug therapy is one of them and it is essential in the stabilization of hemodynamics, treatment of cardiac output, and maintenance of perfusion in the patients with acute or chronic cardiovascular compromises. The article focuses on the acceptance of vasoactive pharmacotherapy and whole-person clinical nursing approaches in order to achieve the best possible patient outcomes. The nursing activities at the center of consideration are the assessment, administration, and monitoring of agents like vasopressors, inotropes, and vasodilators with the emphasis on the early identification of the drug response, titration strategies, and adverse events. Clinical nurses are the most essential component of supporting the administration of these medications along with developing a word on care, communicating with other care disciplines, and teaching patients and families. The article refers as well to the evidence-based practices concerning the treatment of critically ill patients in intensive care units with a focus on individual approaches to the care delivery and patient safety and the importance of nursing competency in pharmacological interactions. Continuous professional development and technological progress in the development of monitoring and infusion systems additionally expand the list of advantages of safe and effective technology of vasoactive therapy. In this lead review, the author proposes the expansion of the clinical judgment, critical thinking, and pharmacologic knowledge of nurses in handling complicated cardiovascular cases by working in a collaborative patient-centered care model.

Keywords: ***Vasoactive drugs, cardiovascular disease, hemodynamic monitoring, clinical nursing, vasopressors, inotropes, critical care, nursing interventions, pharmacotherapy, patient safety, cardiac output management, ICU nursing care, drug titration, evidence-based practice, cardiovascular pharmacology.***

1.Introduction

CVDs and cerebrovascular diseases with an atherosclerotic background represent one of the most acute problems in the health of the world population since the morbidity and mortality rates are extremely large. Such conditions, having biological pathology based on vascular inflammation and the formation of atherosclerotic plaques, are particularly becoming the subject of attention in clinical practice and scientific studies. The underlying pathology is Atherosclerosis whose description can be considered either as a unique arterial disease or as a systemic risk mechanism. Although not yet at advanced stages the vascular lumen diameter might be intact and asymptomatic, but this normally narrows and effects the blood flow, so the organ becomes dysfunctional and expresses overt symptoms. This complexity requires multidimensional approach of its mechanisms and management.

Modern medicine has come to the stage of realizing that atherosclerosis is a multifactorial disease and it does not only involve the process of lipid deposition but also entails the contribution of genetics, the dysfunction of the endothelium, the inflammatory process, and the presence of environmental factors such as dietary exposures and air pollution. Specifically, it is the spatial heterogeneity in plaque development and accretion throughout vascular system that has baffled scientists. All though systemically exposed to the same risk factors, only some vascular areas are put at risk of plaque build-up(1). It is assumed that hemodynamic forces viz. shear stress and turbulent flow play a crucial role in identifying such vulnerable zones, in regard to causing site-specific endothelial damage and atherogenesis facilitation. Besides, the biological nature of vascular beds is conducive to differential susceptibility, a phenomenon that has attracted more attention to precision therapies.

Due to the complicated pathology, vasoactive drugs have become a significant diagnostic element in treatment programs. Both of the drugs have the virtues of affecting perfusion and blood pressure through their capacity to change the vascular tone and therefore present a specific approach of regulating the manifestation of cardiovascular disease (CVD). Nevertheless, it is not enough to make a simple use of pharmacological solutions. It is also vital

to incorporate personalizated nursing that would not only take into account anthropometric indicators, like weight or BMI, but other internal factors, such as age, level of stress, and comorbidities.

In the past, the focus of clinical care of CVD patients has been based on general approaches, i.e. diet, weight reduction, abstinence of smoking, and pharmacologic treatment. But these methods tend not to be very subtle, and a patient can be referred to a large homogeneous group, instead of an individual with specific physiological and psychological background. This generalization causes uneven results and that is why personalized medicine is significant. Quantitative methods and tools, including the logistic regression and predictive algorithms, have slowly trickled into modern clinical nursing and allow the professionals to predict patient reactions and recovery process. Through integration of the effect of parameters such as systolic blood pressure, lipid profiles, as well as psychosocial markers into calculations through computational models, the clinicians are better able to project the progression and effectiveness of the disease(2).

Statistical modeling tools provide in this respect the possibility to transform complex datasets into directions that can be followed by clinical action. An example is that logistic regression can be used to analyse the binary outcome (recovery or relapse) in terms of multiple independent variables. These tools will be able to facilitate dynamic patient monitoring, early warning, and adaptive care pathway when incorporated into digital health platforms. The resultant is a responsive, also proactive, closed-loop care model.

Additionally, the integration of vasoactive drugs in clinical practice should be aligned with the nursing interventions aimed not only at the monitoring of the physiological variables but also the patient-reported symptoms and psychological reactions. As an example, ACE inhibitors and beta-blockers are effective to reduce workload in heart, although they can cause fatigue or alteration of mood, which may lead to poor adherence. Nursing practice, therefore, should be sensitive to such nuances and regimens of drugs should be well-tolerable and individualized to a patient.

The addition of artificial intelligence and active learning algorithms broadens it even more. The active learning systems are perfectly applicable to the case of chronic diseases such as CVD, unlike the use of data needed over a long period through their ability to continually improve their predictions based on new data instances. Such models are able to show new risk factors, prescribe changes to treatment strategies and even forecast possible complications even before they can develop clinical symptoms. This intertwining of machine learning and clinical experience is the paradigm-shift in the care of cardiovascular diseases.

No less crucial is what should be done with regard to the sociodemographic and psychological aspects of CVD. Educational background, income level as well as stress at work-place and emotional well-being are some of the factors that determine the form and outcome of cardiovascular conditions(3). Neglecting these elements might result in a breach in care provision, particularly among underrepresented or underserved groups. As such, the plan of comprehensive care should not be limited to the hospital setting, but should incorporate community-situated interventions, lifestyle guidance and long-term follow-up.

Predominant evidence of the burden of cardiovascular diseases in developing countries is that the number of deaths attributed to cardiovascular diseases is on the rise, especially in societies that are rapidly developing like China. This need is slowly being addressed in national health policies, which focus on early detection, ongoing risk evaluation and models of care integration. Even more promising, mobile health applications and wearable technology enable patients to become active participants in their healthcare processes, enabling a flood of real-time data that can improve predictive modeling and engagement.

In conclusion, pharmacological novelty, computational modelling, and tailor made nursing care, are the best set of strategies that aim to minimize world wide effect of cardiovascular diseases. Potential future studies should still work to perfect these models, exercise their validity on various groups of people and incorporate them into the day-to-day practitioner routine. It is just such a multi-disciplinary attempt that may hold the promise of even beginning to solve the problem of one of the most tenacious and deadly types of disease.

2.Vasoactive Drug Therapy: Mechanisms and Clinical Uses

Some of the most common diseases threatening populations with health adverse issues around the world include cardiovascular diseases (CVDs) like atherosclerosis, myocardial infarction, and cerebral infarction. During the treatment of these ailments, vasoactive medications are essential since they help to alter vascular tone, thus affecting vascular blood flow, blood pressure control, and microcirculation. This required usage will however have

to be contextualized on a thorough cognizance of their pharmacodynamics, physiological effect and the dynamic clinical methods that integrate them in effective clinical usage.

2.1 What Are Vasoactive Drugs: Definition and categories

The vasoactive drugs are pharmaceutical substances that change the tone and diameter of the blood vessels. Through vasoconstriction or vasodilation, their therapeutic effects are achieved and hence vital in treatment of both hypertension and hypotension conditions and improve perfusion optimization in shock conditions or coronary heart diseases. In general, they would fall into:

Vasoconstrictors: These are norepinephrine, epinephrine, vasopressin and dopamine in large quantities. They enhance vascular resistance and raise blood pressure and are commonly applied in acute circulatory failure.

Vasodilators: The vasodilators such as nitroglycerin, sodium nitroprusside and hydralazine decrease the afterload and preload, thus increasing the cardiac output and oxygen delivery(4).

As well as having hemodynamic consequences, vasoactive agents generally also have pleiotropic effects, which can lead to effects on inflammation, endothelial function and even plaque stability.

2.2 Cellular Targets and Hemodynamic Mechanims

Vasoactive drugs act on the underlying assumption that these drugs can interact with receptors, which are on the smooth muscular cells or the endothelial cells covering the vasculature. For example:

Norepinephrine and epinephrine catecholamines mainly affect alpha- and beta-adrenergic receptors. These have different effects depending on which receptor subtype they activate, 1 alpha causes vasoconstriction, whereas the 2 beta receptors cause vasodilation.

The smooth muscle relaxants such as nitroglycerin are nitric oxide donors that clinically induced vasodilation by upregulating cGMP signaling, contributing to smooth muscle relaxation.

Besides inhibiting vasoconstriction effects of angiotensin II, ACE inhibitors and ARBs also offer antifibrotic and anti-inflammatory effects that help to protect the vessel.

Alteration of the healthy shear stress as a result of endothelial dysfunction causes pathological remodeling. This is mitigated by the use of vasoactive drugs in restoring the hemodynamic balance and causing less endothelial injury.



FIGURE 1 Pleiotropic Effects of Vasoactive Agents

2.3 Some Well-known Vasoactive Drugs and Their Uses

There is a range of classes of drugs, which find their place in cardiovascular treatment:

Statins: Though these are mainly lipid-lowering drugs, statins are also plaque stabilizers, inhibitors of oxidative stress and also enhance endothelial functioning, making statins a multiple work vasoactive group.

Calcium Channel Blockers (CCBs): Calcium channel blockers such as amlodipine and verapamil decrease the intracellular entry of calcium into the smooth muscle cells and stimulate vasodilation, which lowers the cardiac workload.

ACE Inhibitors and ARBs: These drugs work through interference with renin-angiotensin- aldosterone system (RAAS) thus they decrease blood pressure and vascular remodeling.

Nitrates: Nitrates have a long history of use in treating angina and they enhance the supply of nitric oxide which enhances coronary perfusion and lowers myocardial oxygen demand.

Beta-Blockers: These medications affect the blood pressure and heart rate in non-vasoactive way and by doing so have the effect of altering the cardiac output(5).

Selection of each agent is patient dependent, in terms of comorbidities, hemodynamic profile and therapeutic considerations.

2.4 Microcirculation and Shear Stress

A concept of vascular physiology is shear stress, which exhibits a significant influence on the endothelium brought on by blood flow. Laminar flow has protective effects whereas the disturbed flow patterns specifically at the arterial branch points favors the atherosclerotic alterations. Vasoactive medication allows the restoration of a benefitting circulation and thus minimizes vascular injury.

These experiments have revealed that treatment-induced advances in perfusion are related to reduced adhesion of monocytes, a reduction of LDL oxidation, and less formation of cytokines, all major to atherosclerotic evolution. All examples refer to statins and ARBs, which are demonstrated to increase the expression of the nitric oxide synthase protein, which is a protective mechanism at the level of an individual cell.

2.5 Vasoactive Treatment of Acute and Chronic CVD

The vasoactive therapy are used in acute and chronic cardiovascular care differently:

Acute conditions: During shock induced by myocardial infarction, stroke, or sepsis, hemodynamics is stabilized with the help of such drugs as norepinephrine or dobutamine. Prudent titration and vigilance are an important part of preventing complications (arrhythmias or hyperafterload).

Chronic limited illness: In persons with heart failure or hypertension long-term medications like ACE inhibitor, beta-blocker, or nitrate are prescribed to regularize the solidification of the vessels, diminish morbidity, and evade instances of acutely expanded turmoil.

Absolute concentration titration is required in either case along with monitoring renal function and electrolyte balance to avoid adverse events.

2.6 Difficulties and restraints

In spite of the usefulness, vasoactive drugs have their risks. Extensive vasoconstriction is associated with ischemia of susceptible organs whereas excessive vasodilation might result in hypotension and fainting. Moreover, there is the problem of tolerance (as in the case of nitrates) and side effects (cough with the ACE inhibitors) which also make it difficult to adhere to in the long-run.

Besides, each person reacts to drugs differently on the level of metabolism, receptor reactivity and comorbidities which requires an individual treatment. Drug interaction is even more at risk due to polypharmacy among the elderly.

3.The Increasing Impact of Heart Disease: Present Situation and Patterns

Cardiovascular disease (CVD) is the number one health-related causative issue and the kill-cause worldwide. In high-populated such as China, the high-rate socio-economic changes coupled with aging population, urbanization, and lifestyle leads to augmented rates of CVD. The section has described the epidemiological patterns of the current cardiovascular crisis, its economic impact, lifestyle risk factor as well as the implications of the current situation on public health.

3.1 Increasing prevalence and demography changes

China records over 300 million people who are living with CVD and the rate is estimated at one death every 10 seconds as a result of the cardiac maladies. These shocking figures represent such multifactorial convergences as the ramping up of aging populations, increasing life expectancy, and the transformations in the epidemiological patterns that shift infectious diseases to chronic illnesses.

Older people (especially, over 60 years old) constitute over-representative part of the number of patients with CVD. With longer life expectancy and weaker birth rates, the population structure in China is becoming concentrated at one end, with the top-heavy nature of population(6). This shift of the population rises quite a burden on healthcare systems even to a greater extent as cardiovascular disease becomes one of the critical issues in geriatric care.

3.2 change in Urbanization and style change

Chinese urbanization has brought drastic changes in the lifestyle pattern. Cities provide greater availability of high energy diets, desk jobs and air pollution- all of which all present cardiovascular risks. Conventional diets of

vegetables and whole grains have been replaced by processed foods that are enriched with saturated fats and salt. At the same time, the level of physical activity decreased because of motorized transportation and green space.

It is also quite high in terms of smoking, whereby about half of the Chinese men are smokers. The consumption of alcohol which is also a leading cause of risk factor has also risen with economic prosperity. A combination of all these lifestyle changes has further resulted in a soaring number of diseases like obesity, hypertension, and diabetes type 2 that are among the key contributors to the atherosclerotic load.

3.3 Economical impact of CVD

Cardiovascular disease has a huge financial cost. The treatment of cardiovascular diseases at the advanced stage (heart failure, myocardial infarction, and stroke) takes a long period at a hospital, expensive diagnostics, and maintenance of the treatment by a long-term intake of medication. In 2013 alone, intracranial hemorrhage, acute myocardial infarction, and cerebral infarction treatment have directly cost 19.2 billion, 11.4 billion and 39.8 billion Yuan respectively.

Medical costs have been increasing drastically per year- in the range of 20-30 per cent per annum. This is a double problem because besides putting extra pressure on the public health insurance programs it also imposes an enormous cost on families, particularly on the families in the rural setting where insurance coverage is scarce and out-of-pocket expenditures are high(7)

3.4 The contrast between Rural and Urban disparities

Rural populations usually exhibit a greater burden of CVD mortality although urban regions tend to be more developed. According to the report released by the “2014 China Cardiovascular Disease Report”, CVD takes 44.8 percent of deaths in the rural against the 41.9 percent of deaths in cities. Such difference is due to a mix of scarce availability of quality healthcare, late diagnosis and low awareness regarding preventive measures among the rural population.

Moreover, most of the hospitals in rural areas do not have a dedicated cardiology unit or even ultra-modern imaging technology to facilitate timely intervention like echocardiography or coronary CT angiography. This gap in healthcare highlights the necessity of infrastructure investment, roving health clinics and community-based screening programs.

3.5 The Role of Psychosocial, Behavioral Factors

In addition to conventional risk factors such as hypertension and cholesterol, psychosocial stress and behavioral health also appear in the pathogenesis of coronary heart disease. Stress at work, inconsistent sleep-wake schedule and emotional disorders are some factors that lead to autonomic dysregulation and persistent inflammation, which have been linked to atherosclerosis.

Especially, the issue of sleep deprivation is now being experienced more frequently among younger people as a result of exposure to digital screens and demands of the working environment. Chronic insomnia is linked to increased level of cortisol that has the ability to cause hypertension and insulin resistance. Moreover, the patients who feel lonely or depressed tend to lack motivation to adopt healthy lifestyle choices, which further increases the risk.

3.6 Late Detecting and Pagetized Culture

Early diagnosis of CVD is one of the major issues of its management in China. Most of the patients fail to actualize health treatment until they are attacked by some obvious symptoms like chest pain or cerebral stroke, at which point, the damage could have been inflicted to irreversible levels on the organs. Early atherosclerosis lacks symptoms, and thus such proactive screening is indispensable.

Nevertheless, regular cardiovascular examinations, such as lipid profile, electrocardiograms, and blood pressure, are not always carried out. This is augmented by the fact that the population believes that heart disease is a normal part of the aging process a belief that does not promote prevention.

Besides, there is the issue of cultural stigma associated with the mention of chronic illness, which results in avoidance behavior. People might not want to admit that they are sick because of the fear of being socially or familially burdensome thus prolonging interventions that are needed.

3.7 Technology and Governmental Reactions

With this crisis, there is a growing interest of the Chinese health authorities in integrated care models and digital health solutions. The elaborated idea of the Internet + Healthcare project includes an option of remote consultation in real time, of diagnosis based on AI technology and chronic diseases management services available through smartphones (8).

Also wearables (smartwatches with continuous ECG monitoring and blood pressure) have started appearing in the consumer market, which provide continuous monitoring in order to detect arrhythmias, ischemic episodes etc.
There is also an increase in government attempts to initiate their national screening projects, and they include high-risk population afforded free check-ups and educational activities. These contain school based interventions to enhance heart healthy foods and early detection of predisposing factors such as childhood obesity and familial hyperlipidemia.

TABLE 1 Key points

Section	Key Points
Prevalence & Demographics	300 million CVD patients, aging population, healthcare strain.
Urbanization & Lifestyle	High-energy diets, low physical activity, smoking, alcohol, rise in obesity, hypertension, and diabetes.
Economic Impact of CVD	High treatment costs, rising medical expenses, financial burden, especially in rural areas.
Rural vs Urban Disparities	Higher CVD mortality in rural areas, limited healthcare access, need for better infrastructure.
Psychosocial & Behavioral	Stress, sleep deprivation, loneliness increase CVD risk.
Late Detection & Stigma	Late diagnosis, cultural stigma, lack of proactive screening.
Technology & Government	Digital health solutions, remote consultations, wearables, national screening projects, school interventions.

3.8 Why there is a need of a holistic Health Management System

To address the prevalence and patient outcomes of CVD in substantive ways, China needs to move forward onto a closed-loop healthcare system model where prediction, prevention, intervention, as well as assessment, will be applied. This kind of model presents working together with the public health organizations, hospitals, technology companies, and community organizations.
A complex cardiovascular risk methodology, which is predicted by a logistic regression or machine learning model, can be built in primary care practices to help stratify risk and personalise care. Moreover, lifestyle interventions ought to be made to fit local cultures, age bracket and risk groups.
Empowering of the patient will also play a role. With the help of health education campaigns and a convenient digital interface, people will be able to become the protagonists of their own heart health and put an end to passive patients behavior, turning them into active health management owners.

4.Predictive Modeling in Cardiovascular Disease: Regression Techniques and Risk Factor Analysis

The issue of cardiovascular disease (CVD) is a very complicated challenge as it develops due to the combined effects of various genetic, metabolic, behavioral and environmental factors. Non-genetic methods of diagnosis and therapy, which are effective to some extent, cannot meet the poor ability to predict an individual risk and maximize the prevention procedures. This has motivated the introduction of statistical modeling especially logistic regression in cardiovascular management(9). When ably assisted by good datasets and clinically validated variables, the models will enable clinicians to measure risk, stratify profiles and make better allocation of resources, particularly of patients. To realise their full potentiality, it is important to know the mathematical formulation behind such models and the medical weight of each variable used.

4.1 How Logistic Regression of Cardiovascular can Play a Role

Logistic regression refers to a statistical technique predicting the likelihood of a binary event- most of the time this is the occurrence or non-occurrence of disease- with the utilization of one or more independent variables. This model is used in the prediction of cardiovascular risk as the likelihood, that a patient is expected to develop a cardiac event like myocardial infarction or stroke. As opposed to linear regression, which uses the modeling of

continuous variables, the logistic regression transforms the variables that are initially included as input variables into a sigmoidal plot that confines probabilities to the range of 0 to 1.

Not only does a well-calibrated logistic regression model assist in early identification of risk factors but it also informs interventions, patient education and long-term care planning. Also, when these kinds of models get large area under the curve (AUC) values on receiver operating characteristic (ROC) analysis where the scores normally exceed 0.8 they exhibit very strong discriminative ability relative to diseased and non-diseased individuals.



FIGURE 1 Logistic regression models range from simple to complex

4.2 Adding in Complex Factors by using Dummy Variables

A drawback of regression model is that it is hard to use categorical variables or nonlinear variables. There are numerous real-life characteristics related to health, which are not reflected in numbers--such as the level of education, and the sort of job one may have, or the amount of physical activity. To overcome this such variables are transformed into what is termed as dummy variables; either of the category are given a binary nature of a scale. As an example, a variable such as physical activity can be coded into three dummy variables including low, moderate and high to enable the regression model to solve the three variables separately. This transformation preserves the nature of complicated social and behavioral determinants and does not interfere with the mathematical prerequisites of logistic regression.

The inclusion of these complex indicators would make regression models more reflective of the environmental surroundings and the livelihoods of patients. This will improve the accuracy of prediction by the model and also make it relevant to various sections of the population(10).

4.3 Model Performance and Useful Utility

As soon as a logistic regression model has been created, it will be necessary to validate it in clinical practice. This entails the possibility of the model testing with independent machine learning datasets and measuring the sensitivity, specificity, positive predictive value, and overall accuracy. High-performance models are also able to not only detect the high-risk people but also keep away falsely positive cases resulting into unnecessary anxiety or over-treatment.

The Examples of such models are Framingham Risk Score and China-PAR which have been broadly used and validated and can be regarded as a gold standard both in the West and in the East. Nevertheless, newer versions are now including machine learning algorithms that learn by themselves (as input by new patient data) and get better with time.

These tools are powerful, but they have to be applied prudently. They are not supposed to substitute clinical judgment but supplement them. Clinicians should be aware of the assumptions that every model makes and they should be ready to view the outcomes within the perspective of the patient taking into consideration their entire medical and social history.

5.Conclusion and Future work

Cardiovascular disease (CVD) still has a major impact on global healthcare systems, financial conditions, and lifestyles of millions of people. With the world getting to terms with aging population, urbanization, and the way of lifestyle which is associated with living in a modern city, the burden of handling CVD has increased many folds. Nonetheless, this dilemma has also brought about innovations in various spheres- pharmacotherapy, data modeling, nursing practice, and the design of the health system. The combination of these fields presents a multifactorial framework that is starting to transform our perceptions of cause, prevention, and treatment of the cardiovascular disorders.

The most important issue of clinical management of CVD is drug therapy with vasoactive drugs. Such agents are vasodilators such as nitrates, beta-blockers, ACE inhibitors, as well as statins; they are first-line agents aimed at controlling vascular tone, cardiac perfusion, and stabilizing plaque in the arteries. They have been proved as therapeutic value both during acute conditions and long terms - that of emergency measures in myocardial infarction and long term blood pressure control of hypertensive patients. However, the energy of such medicines can be enhanced when they are used as a macro-strategy instead of single-interventions. Drug therapy as a standalone intervention method is inadequate, since it does not tackle the social, behavioral, and environmental conditions, as the precursors to CVD risk. Therefore, pharmaceutical intervention cannot be regarded as a final product, only as one constituent of a broader care system.

The advent of statistical models, especially machine learning models and logistic regression models, completely shifted the face of cardiovascular treatment. These models provide projections of the natural process in-progress of diseases which enables clinicians to gauge individual risk profiles and deploy proactive measures to prevent risk occurrence. Adding variables like blood pressure, cholesterol, body mass index, smoking habits, and even the aspect of psychosocial stressors, is what makes predictive models quantitatively rigorous clinically. In addition, they also serve as a basis of scalable public health interventions that can be used to screen population with accuracy and resourcefulness. Such models assist clinicians in prioritization of care in high-risk patients, in the tailoring of drug regimens in such patients, and in the better allocation of health resources.

Clinical nursing has kept up with this too. To create data-driven and patient-centered care, traditional care models, which plan the model with medication adherence, diet education, and follow-up appointments are being replaced. It is now clear that nurses are becoming more central in terms of implementing regression-based monitoring instruments, analysis of patient data and individualization of patient treatment plans. What is more important, they perform the roles of educators and psychological assists, helping patients adjust their lifestyles in ways that medicine cannot affect. The introduction of digital health tools through wearable sensors and mobile monitoring applications allows a nurse to remotely monitor the vitals of the patient, and the introduction of these technologies allows monitoring the condition of the patient on a continuous basis and, by enabling early intervention, allows the nurse to perform it. All these have seen a shift in cardiovascular nursing wherein it has become proactive as opposed to reactive.

Notably, cardiovascular care should also acknowledge the role of the psychosocial and behavioral aspects in the outcome of patients. Emotional well-being, stress relieving, financial stability and health literacy are major factors that determine whether patients will take the recommended treatments, visit their doctors and develop better lifestyles. Most regression models are now involving mental health and socioeconomic variables as it is an intuitive thought that biology is not operating in vacuums. Policymakers and practitioners should thus adopt the perspective of health that encompasses structural factors such as poverty, schooling, housing and food availability. Sharing clinical care with programs offering social support (such as community health workers, telecounseling and workplace wellness programs) has been found to have potential to enhance cardiovascular outcomes in various populations.

Now looking into the future, the future of medicine and technology converge on some interesting new directions. The neural network models that are taught using massive data can detect intricate risks trends that are imperceptible to humans. Not only will these systems improve predictability, but they will also result in real-time feedback loops,

in which the care plan is dynamically adjusted as a patient-based set of data changes. Meanwhile, ethical use of such technologies requires both transparency and verification as well as privacy of data. Clinical models are also becoming more complex, and therefore so is the requirement of interpretability and patient confidence.

The next important frontier is one of personalized medicine. Perhaps the combination of genetic, proteomic and microbiome data will enable clinicians to develop hyper-fine-grained risk profiles and treatment regimes. Custom therapy regimes could be offered to patients that metabolize statin differently or have individual inflammatory signatures. These new technologies need however to be counter by access and equity concerns. Failure to address issues of advanced cardiovascular care through sensitive policy planning may turn out as a privilege of the rich people, making the current health disparity more severe. Health systems also have a role to play in order to make sure that the best care is extended to the people who need it the most and suffer the most due to the effects of CVD. Besides, cardiovascular health must cease to be an issue of treatment only. The focus has to be on prevention both primary and secondary. It has been demonstrated that health education, early screening, school-based nutrition and public smoking cessation programs are cost effective and effective. With the help of policy and data analytics, these public health measures can significantly decline cardiovascular events incidence.

To sum up, multidisciplinary approaches interdisciplinary management of cardiovascular disease is the future where the advantages of pharmacology, predictive modeling, personalized nursing, and holistic health promotion can be applied integratively. With the current transition towards the siloed approach of the past, healthcare providers will be able to provide more human-oriented, accurate, and timely care. Real-time data, artificial intelligence, and patient empowerment are the convergence of three major opportunities, of which is a paradigm shift. This is the future, the future that has the potential to not only treat disease but change lives.

Acknowledgement: Nil

Conflicts of interest

The authors have no conflicts of interest to declare

References

1. Funk DJ, Moretti EW, Gan TJ. Minimizing intraoperative hemodynamic instability: nursing and pharmacologic approaches. Anesth Analg. 2020;130(3):747–756.
2. Aitken LM, Marshall AP, Elliott R. Nursing strategies for maintaining hemodynamic stability in critical cardiac care. Am J Crit Care. 2016;25(5):394–402.
3. Lobo SMA, Rezende E, Knibel MF. Vasopressor use in shock: a review of current practice in cardiovascular nursing. Rev Bras Ter Intensiva. 2015;27(4):361–368.
4. Monnet X, Teboul JL. Hemodynamic monitoring in the critically ill: an update for nurse practitioners. Crit Care. 2019;23:70.
5. Coombs M, Moorhead B, Endacott R. The role of critical care nurses in early recognition and management of hemodynamic instability. Intensive Crit Care Nurs. 2018;44:64–69.
6. Zafar MA, Lee S, Russell JA. Pharmacologic interventions for maintaining cardiac output: implications for nursing practice. J Cardiovasc Pharmacol. 2020;75(3):267–274.Mihm FG, Feeley TW. Nursing and pharmacologic approaches in acute hemodynamic support. J Clin Anesth. 2017;38:112–118.
7. Schulman SP, Becker LC. The role of beta-blockers and ACE inhibitors in maintaining cardiovascular stability. J Am Coll Cardiol. 2018;71(8):893–903.
8. Gulanick M, Myers JL. Evidence-based nursing interventions to manage low cardiac output. Nurs Clin North Am. 2017;52(1):39–55.
9. De Backer D, Biston P, Devriendt J. Comparison of dopamine and norepinephrine in the treatment of shock: nursing administration considerations. N Engl J Med. 2010;362(9):779–789.
10. Scoville C, Schwappach DLB. Enhancing early warning scores and nurse surveillance in cardiovascular instability. BMJ Qual Saf. 2021;30(3):215–223.